Trade Report: The Intercept Pharmaceuticals’ (ICPT) Positive Rating Reaffirmed at Leerink Swann

The Intercept Pharmaceuticals’ (ICPT) Positive Rating Reaffirmed at Leerink Swann

Leerink Swann reaffirmed their positive rating on shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) in a report published on Friday. The firm currently has a $159.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the stock. Wedbush reissued an outperform rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, October 7th. Wells Fargo & Co. reaffirmed a buy rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 28th. Robert W. Baird reaffirmed an outperform rating and set a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, September 22nd. Credit Suisse Group AG reaffirmed a buy rating on shares of Intercept Pharmaceuticals in a research note on Thursday, September 22nd. Finally, JMP Securities reaffirmed a buy rating on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Five equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $178.62.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 3.361% during trading on Friday, reaching $137.681. 200,618 shares of the company traded hands. The company’s market capitalization is $3.40 billion. The stock’s 50 day moving average is $155.48 and its 200 day moving average is $151.28. Intercept Pharmaceuticals has a 1-year low of $89.76 and a 1-year high of $217.99.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.69) by $0.55. The business had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The firm’s quarterly revenue was up 1140.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.99) earnings per share. On average, analysts forecast that Intercept Pharmaceuticals will post ($16.31) EPS for the current year.

In other news, CMO David Shapiro sold 411 shares of the business’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $153.34, for a total transaction of $63,022.74. Following the completion of the sale, the chief marketing officer now directly owns 44,272 shares of the company’s stock, valued at $6,788,668.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Lisa Bright sold 246 shares of the business’s stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the sale, the insider now directly owns 18,460 shares of the company’s stock, valued at $2,935,140. The disclosure for this sale can be found here. Insiders own 9.20% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Aperio Group LLC increased its stake in Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 512 shares during the last quarter. BlackRock Inc. increased its stake in Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,438 shares during the last quarter. BlackRock Group LTD increased its stake in Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 2,188 shares during the last quarter. BlackRock Fund Advisors increased its stake in Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares during the last quarter. Finally, State Street Corp increased its stake in Intercept Pharmaceuticals by 27.5% in the first quarter. State Street Corp now owns 521,407 shares of the biopharmaceutical company’s stock valued at $66,990,000 after buying an additional 112,431 shares during the last quarter. 81.83% of the stock is owned by institutional investors.

About Intercept Pharmaceuticals

Related posts

Leave a Comment